Clinical Practice Guidelines for the management of locally advanced ...

7.5 Q2: Symptom control .............................................................................................. 98
7.5.1 Pain control .................................................................................................... 99
7.5.2 Fatigue ........................................................................................................... 99
7.6 Q3: Effective end-of-life care ..................................................................................... 99
7.7 Summary ................................................................................................................... 100
8 Complementary and alternative therapies ........................................................................ 105
8.1 Definitions ................................................................................................................ 105
9 Socio-economic aspects of advanced prostate cancer ....................................................... 110
9.1 Introduction ............................................................................................................... 110
9.2 Socio-economic status .............................................................................................. 110
9.3 Accessibility ............................................................................................................. 110
9.4 Indigenous groups ..................................................................................................... 111
9.5 Ethnicity and race ..................................................................................................... 111
9.6 Literacy and language ability .................................................................................... 111
9.7 Social support ........................................................................................................... 111
9.8 Socio-economic status and involvement in randomised controlled trials ................. 112
9.9 Socio-economic status implications for these guidelines ......................................... 112
10 Emerging therapies .............................................................................................................. 115
10.1 For men with locally advanced disease .................................................................... 115
10.2 For men with biochemical relapse following definitive therapy .............................. 115
10.3 For men with metastatic disease ............................................................................... 115
10.4 For men with castrate resistant prostate cancer ........................................................ 116
Appendix 1 Guideline development process .............................................................................. 117
Appendix 2 Working party members and contributors ........................................................... 124
Appendix 3 TNM classification of prostate tumours ................................................................ 129
Appendix 4 Abbreviations and glossary .................................................................................... 133
Appendix 5 Further references ................................................................................................... 142
Appendix 6 Organisations which provide information and/or support
for men with advanced prostate cancer ................................................................ 143
Appendix 7 Conflict of Interest summary for working party members ................................. 144
Index ................................................................................................................................... 149
Contents v